STOCK TITAN

Procaps Group S.A - PROC STOCK NEWS

Welcome to our dedicated news page for Procaps Group S.A (Ticker: PROC), a resource for investors and traders seeking the latest updates and insights on Procaps Group S.A.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Procaps Group S.A's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Procaps Group S.A's position in the market.

Rhea-AI Summary
Procaps Group has announced the appointment of Sandra Sánchez y Oldenhage as a Director to its Board of Directors. Sandra brings over 35 years of experience in the pharmaceutical industry and has held various leadership positions in major companies. Her appointment is expected to contribute to the growth and expansion of Procaps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.84%
Tags
management
-
Rhea-AI Summary
Procaps Group announces participation at CPHI Barcelona 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
conferences
-
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) will host a webinar on October 10th to discuss the Colombian pharma market and its regulations. The webinar will be led by Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
Rhea-AI Summary
Procaps Group, S.A. (NASDAQ: PROC) announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
-
Rhea-AI Summary
Procaps Group expands its oncology portfolio in Latin America through an agreement with BDR Pharmaceuticals for 27 oncology molecules, including 20 TKIs. Procaps will handle registration, branding, marketing, and commercialization throughout Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
none
-
Rhea-AI Summary
Procaps Group reports 7% increase in net revenues in 1H23 YoY on a constant currency basis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
Rhea-AI Summary
Procaps Group to report Q2 and six months results on September 5, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences earnings
-
Rhea-AI Summary
Procaps Group introduces a new high temperature gummy technology platform to solve formulation and distribution challenges. The white paper explores the problem of maintaining gummy product quality and integrity during the supply chain, particularly in the summer season. Funtrition®, a division of Procaps, offers innovative gummy technologies that increase the thermal resistance of gummies, addressing the challenges of temperature fluctuation. The white paper highlights Procaps' commitment to meeting market demands and requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Procaps Group S.A

Nasdaq:PROC

PROC Rankings

PROC Stock Data

303.50M
17.15M
83.03%
3.19%
0.01%
Medicinal and Botanical Manufacturing
Manufacturing
Link
LU
Luxembourg City

About PROC

procaps group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. we have direct presence in 13 countries in latin america and we have more than 5,000 collaborators working under a sustainable model. we develop, manufacture, and market over-the-counter (otc) and prescription drugs, nutritional supplements and high-potential clinical solutions.